Association of Asprosin in Periodontitis and Acute Coronary Syndrome

Cardiovascular Diseases Clinical Trial

Official title:

Serum Asprosin Concentrations in Patients With Periodontitis and Acute Coronary Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05647902
• Other study ID #: MIC3
• Status: Completed
• Start date: January 1, 2022
• Est. completion date: January 1, 2023

Study information

• Verified date: July 2023
• Source: Ataturk University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Asprosin, a recently discovered glucogenic adipokine, is mainly synthesized by white adipose tissue and released during fasting. Appetite, glucose metabolism, insulin resistance, cell apoptosis, etc. asprosin is associated with diseases such as diabetes, obesity, polycystic ovary syndrome, and cardiovascular diseases. Periodontal tissue may act as a source of endocrine-like inflammatory mediators (such as TNF-α, IL-6 and IL-1) that are important in periodontal inflammation and can affect glucose and lipid metabolism. Production of TNF-α and IL-6 in adipose tissues strengthens the relationship between cardiovascular diseases and periodontitis. Investigators postulated that asprosin may be a candidate for explaining the triangular relationship between cardiovascular and periodontal disease.

Description:

Periodontal disease is a chronic, multifactorial, and infectious disease caused by bacteria. It is characterized by the formation of an inflammatory response in the supporting bone and connective tissue against microbial dental plaque, and the nature of the resulting inflammatory response determines the course of periodontal disease. Cardiovascular and periodontal diseases are closely related, presenting a triad association. Asprosin circulates in the blood at nanomolar levels and is taken to the liver, where it activatesinvestigators the G protein-cAMP-PKA pathway, causing rapid glucose release into the circulation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: January 1, 2023
• Est. primary completion date: December 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

For Healthy group

• All individuals were generally healthy,
• non-smoking For Myocard Infarctus group
• patients with ST elevation of Myocardial Infactus
• patient with less than ten teeth

Exclusion Criteria:

• Smokers or those with diabetes or other inflammatory disease
• Pregnant or breastfeeding women
• None had undergone periodontal therapy and/or antibiotic therapy in the past 6 months.
• None has a contagious disease such as HIV or AIDS

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Cardiovascular Diseases
• Periodontal Diseases
• Periodontitis

Intervention

Diagnostic Test:
• Serum samples will be collected. Asprosin levels will be determined by biochemical analysis
Serum samples will be collected from both groups for biochemical analysis.

Locations

Country	Name	City	State
Turkey	Atatürk University Faculty of Dentistry	Erzurum

Sponsors (1)

Lead Sponsor	Collaborator
Ataturk University

Country where clinical trial is conducted

Turkey, 

References & Publications (2)

Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, Saha PK, Del Solar M, Zhu B, York B, Sarkar P, Rendon DA, Gaber MW, LeMaire SA, Coselli JS, Milewicz DM, Sutton VR, Butte NF, Moore DD, Chopra AR. Asprosin, a Fasting-Induced Glucogenic Prote — View Citation

Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: A Novel Player in Metabolic Diseases. Front Endocrinol (Lausanne). 2020 Feb 19;11:64. doi: 10.3389/fendo.2020.00064. eCollection 2020. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Asprosin Levels	Determination of asprosin levels by making biochemical analyzes from serum	two weeks